CTX Captor Therapeutics Spolka Akcyjna

12.98USD52.20 PLN · GPW-0.19%Mkt Cap: 82.19M USDP/E: —

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that …

Key Statistics

Company
Market Cap82.19M USD
Enterprise Value65.34M USD
Revenue (TTM)498.70K USD
Gross Profit799.27K USD
Net Income (TTM)-10.44M USD
Revenue/Share0.09 USD
Last Price12.98 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLCPTRT00014
Valuation
P/E (Trailing)—
P/E (Forward)-12.25
PEG—
EV/EBITDA-6.15
EV/Revenue131.01
P/S164.81
P/B5.10
EPS (TTM)-1.96 USD
EPS (Forward)—
52W Range
11.1417% of range22.18
52W High22.18 USD
52W Low11.14 USD
Profitability
Gross Margin68.99%
Oper. Margin-2311.12%
EBITDA Margin0.00%
Profit Margin-901.22%
ROE-178.86%
ROA-104.93%
ROIC—
ROCE-173.76%
Growth
Revenue Growth-18.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.28M USD
CapEx (TTM)52.21K USD
FCF Margin-1220.59%
FCF Yield-7.41%
Net Debt-17.11M USD
Net Debt/EBITDA1.61
Net Debt/FCF—
Balance Sheet
Debt/Equity0.15
Current Ratio5.41
Quick Ratio5.41
Book Value/Sh2.55 USD
Cash/Share2.80 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)22.85 USD
Upside (mean)+76.1%
Target Range16.66 USD – 27.35 USD
16.66+76.1% to mean27.35
# Analysts3
Ownership
Shares Out.6.33M
Float5.01M
Insiders29.27%
Institutions32.50%
Technical
SMA 5015.40 (-15.8%)
SMA 20018.31 (-29.1%)
Beta0.65
S&P 52W Chg12.00%
Avg Vol (30d)7.52K
Avg Vol (10d)4.12K
Technical Indicators
RSI (14)37.0
MACD-2.4259
MACD Signal-2.8435
MACD Hist.+0.4176
BB Upper14.40 USD
BB Middle13.34 USD
BB Lower12.28 USD
BB Width15.87%
ATR (14)0.6168 USD
Vol Ratio (20d)1.17x

About Captor Therapeutics Spolka Akcyjna (WSE: CTX)

›

Captor Therapeutics Spolka Akcyjna (WSE: CTX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 82 employees.

The shares were at 52.20 PLN on 19 November 2026, up 18.4% over 52 weeks. Its 52-week range is 44.80 PLN to 89.20 PLN: the price is 41.5% below the high and 16.5% above the low.

Its market capitalisation is 330.60M PLN.

Captor Therapeutics Spolka Akcyjna reports return on equity of -178.9% and revenue down 18.7% year over year.

It holds more cash than debt, a net cash position of 68.84M PLN. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 91.90 PLN is 76.1% above the current price.